Ticker League

Cash on Hand for Pfizer (PFE)

As of · Reported

Metric

Latest period

$13.07B

YoY change

-33.6%

5Y CAGR

+2.2%

Peak year (2014)

$36.12B

Cash on Hand history chart for Pfizer (PFE) from 1985 to 2025

Latest: $13.60B

Cash on Hand growth chart for Pfizer (PFE) from 1985 to 2025

Latest: -33.6%

Cash on Hand history table for Pfizer (PFE) from 1985 to 2025

  • 2025$13.60B-33.6%
  • 2024$20.48B+61.4%
  • 2023$12.69B-44.2%
  • 2022$22.73B-26.8%
  • 2021$31.07B+154.2%
  • 2020$12.22B+26.7%
  • 2019$9.65B-48.8%
  • 2018$18.83B-5.8%
  • 2017$19.99B+12.0%
  • 2016$17.85B-23.4%
  • 2015$23.29B-35.5%
  • 2014$36.12B+11.5%
  • 2013$32.41B+0.0%
  • 2012$32.40B+22.5%
  • 2011$26.45B-5.6%
  • 2010$28.01B+7.9%
  • 2009$25.97B+9.4%
  • 2008$23.73B-6.8%
  • 2007$25.48B-8.1%
  • 2006$27.71B+24.7%
  • 2005$22.23B+11.7%
  • 2004$19.89B+66.4%
  • 2003$11.95B-4.8%
  • 2002$12.55B+45.7%
  • 2001$8.62B+25.5%
  • 2000$6.86B+7.5%
  • 1999$6.39B+311.5%
  • 1998$1.55B+77.0%
  • 1997$877.00M-23.7%
  • 1996$1.15B+185.1%
  • 1995$403.30M-72.3%
  • 1994$1.46B+100.0%
  • 1993$729.40M-42.0%
  • 1992$1.26B-4.6%
  • 1991$1.32B+51.4%
  • 1990$870.30M+5.4%
  • 1989$825.40M+2.2%
  • 1988$807.50M-21.7%
  • 1987$1.03B+158.7%
  • 1986$398.60M-3.4%
  • 1985$412.60M—

Cash on Hand values are taken from Pfizer's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Cash on Hand at Pfizer (PFE)

According to Pfizer's latest reported financial statements, the company's latest reported cash and short-term investments is $13.07B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

In 2025, Pfizer (PFE) cash and short-term investments totalled $13.60B – plunged 33.6% year-over-year.

Through 2020–2025 (5 years), Pfizer cash and short-term investments delivered a +2.2% annualised rate; with mixed annual results across the window.

Between 2014 and 2025, Pfizer cash and short-term investments plunged 62.4%, falling from $36.12B to $13.60B.

The highest annual cash and short-term investments of $36.12B was reported in 2014. The lowest in the available history was $398.60M in 1986.

Pfizer Cash on Hand by Year

Pfizer Cash on Hand 2025: $13.60B

Pfizer cash and short-term investments in 2025 was $13.60B, plunged 33.6% below 2024.

Pfizer Cash on Hand 2024: $20.48B

2024's cash and short-term investments for Pfizer came in at $20.48B, surged 61.4% from 2023.

Pfizer Cash on Hand 2023: $12.69B

Pfizer posted cash and short-term investments of $12.69B in 2023, plunged 44.2% below 2022.

Pfizer Cash on Hand 2022: $22.73B

In 2022, Pfizer reported cash and short-term investments of $22.73B, declined 26.8% below 2021.

Pfizer Cash on Hand 2021: $31.07B

Pfizer cash and short-term investments in 2021 was $31.07B.

See more financial history for Pfizer (PFE).

Sector peers by Cash on Hand

Healthcare peers of Pfizer (PFE), ranked by their latest cash and short-term investments

Frequently asked questions

Pfizer (PFE) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview